Reported 17 days ago
AstraZeneca's market valuation has dropped significantly to around £150 billion amid concerns stemming from a Chinese investigation into its operations, including alleged illegal drug importation and data privacy breaches. The company's CEO, Pascal Soriot, faces challenges as the fallout from these investigations could be prolonged, with comparisons being made to past issues faced by other pharmaceutical companies like GSK. Despite recent promising developments in its experimental products, investor confidence remains shaken.
Source: YAHOO